Silence Therapeutics PLC
Company Profile
Business description
Silence Therapeutics PLC is a biotechnology company focused on discovering and developing novel molecules incorporating short-interfering ribonucleic acid or siRNA. Using its mRNAi GOLD platform, the company has generated siRNA product candidates both for internal development pipeline as well as for out-licensed programs with third-party collaborators. Its wholly owned pipeline is focused on three therapeutic areas: cardiovascular disease, hematology, and rare diseases. The different product candidates in its pipeline are Divesiran (SLN124), a siRNA product candidate that has the potential to treat several hematological disorders; Zerlasiran (SLN360), being developed as a potential treatment to reduce cardiovascular issues; SLN-312; SLN-548; and multiple other programs.
Contact
72 Hammersmith Road
LondonW14 8TH
GBRT: +44 2034576900
Sector
Healthcare
Stock type
Defensive
Industry
Biotechnology
Fiscal Year End
31 December 2025
Employees
116
Stocks News & Analysis
stocks
Ask the analyst: How reliant are Guzman shares on international growth?
Morningstar Investment Ideas
Markets
Index | Last price | Change | % Change |
---|---|---|---|
All Ordinaries | 9,006.80 | 116.00 | 1.30% |
CAC 40 | 7,822.67 | 0.67 | 0.01% |
DAX 40 | 24,289.51 | 81.42 | -0.33% |
Dow JONES (US) | 44,342.19 | 142.30 | -0.32% |
FTSE 100 | 8,992.12 | 19.48 | 0.22% |
HKSE | 24,825.66 | 326.71 | 1.33% |
NASDAQ | 20,895.65 | 10.01 | 0.05% |
Nikkei 225 | 39,819.11 | 82.08 | -0.21% |
NZX 50 Index | 12,880.40 | 25.01 | -0.19% |
S&P 500 | 6,296.79 | 0.57 | -0.01% |
S&P/ASX 200 | 8,757.20 | 118.20 | 1.37% |
SSE Composite Index | 3,534.48 | 17.66 | 0.50% |